Elevated levels of the receptor for advanced glycation end products, a marker of alveolar epithelial type i cell injury, predict impaired alveolar fluid clearance in isolated perfused human lungs

Chest

Volumn 135, Issue 2, 2009, Pages 269-275

  Briot, Raphael ^a   Frank, James A ^b   Uchida, Tokujiro ^c   Lee, Jae W ^a   Calfee, Carolyn S ^b   Matthay, Michael A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Acute lung injury; Alveolar epithelial fluid transport; Alveolar epithelial permeability; ARDS; Lung transplantation; Primary graft failure; Receptor for advanced glycation end products; Von willebrand factor

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BIOLOGICAL MARKER; VON WILLEBRAND FACTOR;

ARTICLE; CELL DAMAGE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM INJURY; EX VIVO STUDY; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG ARTERY PRESSURE; LUNG FLUID; LUNG INFILTRATE; LUNG PERFUSION; MEASUREMENT; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL;

EID: 60249099585     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.08-0919     Document Type: Article

References (26)

1. Ware LB, Wang Y, Fang X, et al. Assessment of lungs rejected for transplantation and implications for donor selection. Lancet 2002; 360:619-620
2. Steen S, Sjoberg T, Pierre L, et al. Transplantation of lungs from a non-heart-beating donor. Lancet 2001; 357:825-829
3. de Antonio DG, Marcos R, Laporta R, et al. Results of clinical lung transplant from uncontrolled non-heart-beating donors. J Heart Lung Transplant 2007; 26:529-534
4. Steen S, Ingemansson R, Eriksson L, et al. First human transplantation of a nonacceptable donor lung after reconditioning ex vivo. Ann Thorac Surg 2007; 83:2191-2194
5. Ware LB, Matthay MA. Alveolar fluid clearance is impaired in the majority of patients with acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2001; 163:1376-1383
6. Ware LB, Golden JA, Finkbeiner WE, et al. Alveolar epithelial fluid transport capacity in reperfusion lung injury after lung transplantation. Am J Respir Crit Care Med 1999; 159:980-988
7. Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173:1008-1015
8. Calfee CS, Ware LB, Eisner MD, et al. Plasma receptor for advanced glycation end-products and clinical outcomes in acute lung injury. Thorax 2008 Jun 19; Epub ahead of print
9. Frank JA, Briot R, Lee JW, et al. Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs. Am J Physiol Lung Cell Mol Physiol 2007; 293:L52-L59
10. Orens JB, Boehler A, de Perrot M, et al. A review of lung transplant donor acceptability criteria. J Heart Lung Transplant 2003; 22:1183-1200
11. Verghese GM, Ware LB, Matthay BA, et al. Alveolar epithe-lial fluid transport and the resolution of clinically severe hydrostatic pulmonary edema. J Appl Physiol 1999; 87:1301-1312
12. Ware LB, Conner ER, Matthay MA. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001; 29:2325-2331
13. Ware LB, Eisner MD, Thompson BT, et al. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med 2004; 170:766-772
14. Calfee CS, Budev MM, Matthay MA, et al. Plasma receptor for advanced glycation end-products predicts duration of ICU stay and mechanical ventilation in patients after lung transplantation. J Heart Lung Transplant 2007; 26:675-680
15. Schmidt AM, Yan SD, Yan SF, et al. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108:949-955
16. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005; 83:876-886
17. Shirasawa M, Fujiwara N, Hirabayashi S, et al. Receptor for advanced glycation end-products is a marker of type I lung alveolar cells. Genes Cells 2004; 9:165-174
18. Gammie JS, Stukus DR, Pham SM, et al. Effect of ischemic time on survival in clinical lung transplantation. Ann Thorac Surg 1999; 68:2015-2019; discussion 2019-2020
19. Fiser SM, Kron IL, Long SM, et al. Influence of graft ischemic time on outcomes following lung transplantation. J Heart Lung Transplant 2001; 20:1291-1296
20. Meyer DM, Bennett LE, Novick RJ, et al. Effect of donor age and ischemic time on intermediate survival and morbidity after lung transplantation. Chest 2000; 118:1255-1262
21. Fischer S, Maclean AA, Liu M, et al. Dynamic changes in apoptotic and necrotic cell death correlate with severity of ischemia-reperfusion injury in lung transplantation. Am J Respir Crit Care Med 2000; 162:1932-1939
22. Snell GI, Rabinov M, Griffiths A, et al. Pulmonary allograft ischemic time: an important predictor of survival after lung transplantation. J Heart Lung Transplant 1996; 15:160-168
23. Thabut G, Mal H, Cerrina J, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med 2005; 171:786-791
24. Rubin DB, Wiener-Kronish JP, Murray JF, et al. Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest 1990; 86:474-480
25. Flori HR, Ware LB, Milet M, et al. Early elevation ofplasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation. Pediatr Crit Care Med 2007; 8:96-101
26. Egan TM, Haithcock JA, Nicotra WA, et al. Ex vivo evaluation of human lungs for transplant suitability. Ann Thorac Surg 2006; 81:1205-1213